GT Biopharma prices USD 7.75 million private placement of Series M preferred, warrants
GTBP•Private placement expanded to USD 7.75 million
GT Biopharma expanded a private placement to raise USD 7.75 million through Series M 10% convertible preferred stock and accompanying warrants.
The amendment increased issuance to 8,611 shares of preferred stock, up from 8,278, with warrants sized to the conversion shares.
Purchasers received greenshoe rights for up to USD 31.21 million of additional preferred stock purchases, subject to adjustments.
The transaction was structured as an unregistered offering under Rule 506(b) of Regulation D.
Related News
Soligenix held annual shareholder meeting, investors backed authorized share increase to 125 million
SNGX•
General Fusion taps PwC after $411.3 million restatement tied to subscription liability valuation error
GFUZ•
